ELTROMBOPAG

Other

Brand names: Eltrombopag Olamine

Oral

Mechanism of Action

12.1 Mechanism of Action Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production.

Indications

immunoglobulins

Contraindications

• 4 CONTRAINDICATIONS None. None. ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS Hepatotoxicity: Monitor liver function before and during therapy
2 ) Increased Risk of Death and Progression of Myelodysplastic Syndromes to Acute Myeloid Leukemia
1 Hepatic Decompensation in Patients With Chronic Hepatitis C In patients with chronic hepatitis C, eltrombopag in combination with interferon and ribavirin may increase the risk of hepatic decompensation
5 g/dL) or Model for End-Stage Liver Disease (MELD) score greater than or equal to 10 at baseline had a greater risk for hepatic decompensation on the arm receiving treatment with eltrombopag plus antivirals

Known Side Effects

8 documented side effects by frequency

Drug Not Working

>10%

Fatigue

1-10%

Headache

1-10%

Nausea

0.1-1%

Diarrhea

0.1-1%

General Unwellness

0.1-1%

Fever

0.1-1%

Weakness

0.1-1%

Community Discussions

No community discussions found for ELTROMBOPAG yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral